E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
hormone receptor positive breast cancer, hormone naive, breast, cancer, neoplasm breast cancer, metastatic, tumour, neoplasm |
|
E.1.1.1 | Medical condition in easily understood language |
hormone receptor positive breast cancer, hormone naive, breast, cancer, neoplasm, metastatic, tumour |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate superior progression free survival for patients treated with fulvestrant 500mg versus patients treated with anastrozole 1mg |
|
E.2.2 | Secondary objectives of the trial |
To compare the overall survival, objective responses, clinical benefit responses, quality of life and safety profile for study patients |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1 Histological confirmation of breast cancer in post menopausal women (age >=60)
2 Positive hormone receptor status (ER +ve and/or PgR +ve) of primary or metastatic tumour tissue based on local laboratory assessment.
3 EITHER locally advanced disease (1 line of chemotherapy allowed only if remain unsuitable for therapy of curative intent) OR Metastatic disease. (1 line of chemotherapy for breast cancer allowed only if subsequent evidence of further progressive disease)
4 At least 1 lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment.
5 Postmenopausal woman, fulfilling 1 of: Prior bilateral oophorectomy/Age ≥60 years/Age <60 years and amenorrheic for 12+months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol in the postmenopausal range
|
|
E.4 | Principal exclusion criteria |
1 Presence of life-threatening metastatic disease - Any of: Extensive hepatic involvement/ involving brain or meninges/ symptomatic pulmonary lymph spread. Discrete lung metastases are acceptable if respiratory function is not significantly compromised
2 Prior systemic therapy for breast cancer other than one line of cytotoxic chemotherapy (the last dose of chemotherapy must have been received more than 28 days prior to randomisation).
3 Radiation therapy if not completed within 28 days prior to randomisation (with the exception of radiotherapy given for control of bone pain, started prior to randomisation).
4 Prior hormonal treatment for breast cancer.
5 Current or prior malignancy within previous 3 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Compare the progression free survival (PFS) in patients treated with fulvestrant with those treated with anastrozole |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline RECIST 1.1 assessments and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease. |
|
E.5.2 | Secondary end point(s) |
1 Compare the Overall Survival (OS, death due to any cause) in patients treated with fulvestrant with those treated with anastrozole when 65% of patients are recorded as having died.
2 Measure objective response rate (ORR) for fulvestrant treatment versus anastrozole. (ORR =% of patients recording partial (PR) or complete response (CR)
3 Measure the duration of response (DoR) for fulvestrant treatment versus anastrozole. (DoR = days from PR/CR response to objective disease progression)
4 Measure expected duration of response (EDoR) for fulvestrant treatment versus anastrozole. (EDoR = p Efp(x), where x=DoR, p=proportion of responders, Efp(x) is mean duration of response)
5 Measure clinical benefit rate (CBR) for fulvestrant treatment versus anastrozole. (CBR= proportion of patients recording RECIST assessments of CR/PR or stable disease (SD) over at least 154 days
6 Measure the duration of clinical benefit (DoCB) for fulvestrant versus anastrozole treatment. (DoCB = for patients recording clinical benefit responses only; days from randomization to date of disease progression)
7 Measure expected duration of clinical benefit (EDoCB) for fulvestrant treatment versus anastrozole. (EDoCB = p Efp(x), where x=DoCB, p=proportion of responders, Efp(x) is mean duration of clinical benefit)
8 Compare the effect of fulvestrant treatment versus anastrozole treatment on Health Related Quality of Life (HRQoL)
9 Compare the safety of fulvestrant treatment versus anastrozole by assessing a panel of adverse events measures: physical examination, electrocardiogram, pulse and blood pressure, weight and haematology and clinical chemistry assessments
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 Following progression, patients will be contacted at 12 weekly intervals to determine survival status
Nos 2-7 Baseline RECIST 1.1 assessments and then every 12 weeks
8 Quality of life questionnaires completed at baseline, 12 weekly whilst on treatment, or 24 weekly for patients being followed for survival
9 Up to the primary analysis: Adverse event will be collected from consent to 56 days after final injection. Vital signs will be collected at each on-treatment visit; ECGs, clinical chemistry and haematology collected from randomization and every 12 weeks until 35 days after final injection. Following the primary analysis, only serious adverse events are recorded.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 21 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Peru |
Ukraine |
Taiwan |
Brazil |
Canada |
China |
Japan |
Mexico |
Russian Federation |
South Africa |
United Kingdom |
United States |
Czechia |
Italy |
Poland |
Slovakia |
Spain |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study database will close after the last patient assessment/visit contributing to the overall survival analysis, which will be conducted when approximately 50% patients have died. The end of the study is defined as the last visit of the last patient, occurring when the last patient has discontinued study therapy |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 10 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 10 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |